



G Medical Innovations Holdings Ltd
ARBN 617 204 743

ASX Announcement

21 May 2018

MISLEADING STATEMENT BY STOCKHEAD IN ARTICLE

G Medical Innovations Holdings Ltd (ASX: GMV) (**G Medical** or the **Company**) would like to provide a response to an article published by media website "Stockhead" on 18 May 2018.

The article stated, amongst other things, that:

"A \$65.7 million deal in July last year to distribute the Prizma case in China seems to have disappeared."

This statement appears to be in reference to the announcement entitled "G Medical Signs Binding MOU for China Distribution" announced on 27 July 2017 (**July Announcement**), which disclosed that a subsidiary of G Medical had executed a binding memorandum of understanding (**MOU**) with Shandong Bolelong Information S&T Co. Ltd (**Boletong**).

The statement made by Stockhead in their article was both false and misleading to investors.

Pursuant to this MOU, and as disclosed in the July Announcement, Bolelong agreed to purchase a minimum quantity of units within the 1st year of the G Medical Smartphone Prizma with minimum commitments being no less than US\$67,500,000. The obligation to acquire the units commences on the granting of the China Food and Drug Administration (**CFDA**) certification to G Medical.

The Company advises that the MOU remains in place and that it is continuing to progress the necessary CFDA certification process which will enable manufacturing to commence in China to satisfy the commitments under the MOU. The Company will provide further updates on the CFDA certification process in accordance with its continuous disclosure obligations.

G Medical was not contacted to provide information for the Stockhead article or respond to any questions about this or any other commentary in the article. G Medical contacted the publisher in this regard and the publisher has agreed to include a clarification in the article addressing this matter.

The Company is considering all its options in ensuring a request for accurate information about the Company is requested and reserves its rights to take legal action in respect of this matter.

-ENDS-

Board of Directors

G Medical Innovations Holdings Ltd

About G Medical Innovations

G Medical (**ASX:GMV**) was founded in August 2014, aiming to be at the forefront of the digital health revolution, developing the next generation of mobile health (mHealth) technologies. The Company brings forth the experience and expertise of its Board to deliver best-in-class solutions to address this global opportunity.

The Company specialises in innovative next generation mobile and e-health solutions and services using its suite of devices and software solutions with a view to driving multiple and recurring revenue streams, across numerous verticals and territories.

For more information on G Medical, please visit www.gmedinnovations.com

For investor enquiries or feedback for the Company that are not related to your shareholding, email investors@gmedinnovations.com